Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Developmental therapeutics / investigational immunotherapy

1756 - Combination Therapy Optimization in Gastrointestinal Cancers using Multi-omic Molecular Profiling


20 Oct 2018


Poster Discussion session - Developmental therapeutics / investigational immunotherapy


Clinical Research;  Translational Research

Tumour Site

Gastrointestinal Cancers


M. Cecilia Monge Bonilla


Annals of Oncology (2018) 29 (suppl_8): viii133-viii148. 10.1093/annonc/mdy279


M..C. Monge Bonilla1, E. Blais2, W. Chen3, M. Pishvain4, E. Petricoin5, J.L. Marshall4

Author affiliations

  • 1 Oncology, National Cancer Institute, National Institutes of Health, 20892-9760 - Bethesda/US
  • 2 Computational Biology Dept., Perthera, 22102 - McLean/US
  • 3 Bioinformatics, Caris Life Sciences, 75039 - Irving/US
  • 4 Lombardi Cancer Center, Georgetown University Hospital, 20007 - Washington/US
  • 5 Scientific Department, Perthera, 22102 - McLean/US


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1756


The majority of new cancer drugs in development target molecular pathways expressed in increasingly smaller subsets of patients. Combination trials will dictate even further enrichment and smaller percentages of eligible patients. Multi-omic molecular profiling (MOMP) from a national research consortium applied to 6 large oncology pipelines permits prospective feasibility and prioritization of clinical research projects.


5377 gastrointestinal cancers that underwent multi-omic molecular profiling (MOMP) were retrospectively analyzed to estimate the potential actionability of single agents and pairwise combinations. Patient-specific actionability was assessed using a heuristic algorithm to match therapeutic agents across 6 oncology pipelines to biomarkers implicated in preclinical and clinical studies.


Single agent actionability was highest across all 5377 patient tumors for agents targeting PI3K/AKT/mTOR signaling (24%), replicative stress via Chk1 (19%), DNA damage repair via PARP/ATR/ATM (15%), RAF/MEK/ERK signaling (13%), PD-1/PD-L1 (7%), and NOTCH signaling (7%). For combinatorial actionability, we found that PI3K/AKT/mTOR pathway alterations often co-occurred with biomarkers associated with sensitivity to agents targeting PARP (9%), NOTCH (6%), and PD-1/PD-L1 (5%). Other promising immunotherapy combinations for specific GI cancer types included MEK, ERK, Chk1, ATR, hedgehog and porcupine inhibitors. We present these analyses in the context of current oncology pipelines.


Use of a computational based analysis of multi-omic molecular tumor profiling data could transform drugdevelopment strategy, agent and drug pipeline prioritization in cancer trial design by providing a mathematically rationalized agent match based on real world molecular data. Before embarking on molecularly enriched single agent or combination clinical trials, prospective analyses should be performed to determine feasibility of accrual, potential clinical utility, and target-specific or disease-specific designs.

Clinical trial identification

Legal entity responsible for the study

Georgetown University Hospital, Lombardi Cancer Center.


Georgetown University Hospital, Lombardi Cancer Center.

Editorial Acknowledgement


E. Blais: Employee: Perthera, Inc. with stock equity holdings/options; Co-inventor: Perthera-assigned patents from and can receive royalties and licensing fees. M. Pishvain: Consultant and Chief Medical Officer: Perthera; Compensation and stock: Perthera. E. Petricoin: Co-founder: Perthera, Inc., Ceres Nanosciences, Inc.; Board of directors and stock equity holder of both companies; Consultant: Perthera, Inc., Ceres Nanosciences, AVDX Investors Group, LLC and AzGen Inc; Coinventor on Perthera-assigned and University-assigned and US Government assigned patents and can receive royalties and licensing fees from both. J.L. Marshall: Scientific advisory board of Perthera, Inc. and Caris Life Sciences. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.